Koyfin Home > Directory > Health Care > Acceleron Pharma > Total Debt / Equity

Acceleron Pharma Total Debt / Equity Chart (XLRN)

Acceleron Pharma annual/quarterly Total Debt / Equity from 2012 to 2020. Debt to equity is a measure of leverage in a company and expressed as a ratio of the total debt relative to book value of equity.
  • Acceleron Pharma Total Debt / Equity for the quarter ending June 06, 2020 was $6m a -7.79% decrease of 0m year over year
  • Acceleron Pharma Total Debt / Equity for the last 12 months ending June 06, 2020 was $6m a -7.79% decrease of 0m year over year
  • Acceleron Pharma Annual Total Debt / Equity for 2019 was $6m a -397.07% decrease of -23m from 2018
  • Acceleron Pharma Annual Total Debt / Equity for 2013 was $29m a 430.49% increase of 126m from 2012
  • Acceleron Pharma Annual Total Debt / Equity for 2012 was $-96m a 162.79% decrease of -157m from 2011
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
View Chart On Koyfin

Quarterly XLRN Total Debt / Equity Data

06/2020$6m
03/2020$6m
12/2019$6m
09/2019$6m
06/2019$6m
03/2019$6m
12/2013$29m
09/2013$25m
06/2013$-387m
03/2013$-107m

Annual XLRN Total Debt / Equity Data

2019$6m
2013$29m
2012$-96m
2011$61m